August 9, 2019

Dear Editor,
World Journal of Gastroenterology

Manuscript No: 48925

Title: “Pathological response measured using virtual microscopic slides for gastric cancer patients who underwent neoadjuvant chemotherapy”

Thank you so much for your comments in the email dated June 26, 2019, concerning our manuscript entitled “Pathological response measured using virtual microscopic slides for gastric cancer patients who underwent neoadjuvant chemotherapy” by Kawai S, *et al.*, for publication in *World Journal of Gastroenterology.* We have studied the reviewer’s comments carefully, and have made revision in accordance with the suggestions, as attached in separate sheets. We herewith resubmit the revised manuscript as a new manuscript.

I believe that the manuscript is now suitable for publication in *World Journal of Gastroenterology.* I hereby certify that this manuscript consists of original, unpublished work that is not being considered for publication elsewhere.

Your consideration of this paper is greatly appreciated.

Yours sincerely,

Sadayuki Kawai, M.D., Ph.D.
Division of Gastrointestinal Oncology, Shizuoka Cancer Center
1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777 Japan
Phone: +81-55-989-5222
Fax: +81-55-989-5634
E-mail: sadayuki-kawai@i.shizuoka-pho.jp

Response to Reviewer #1

First of all, we thank so much for your evaluation of our study and giving us a number of precious comments.

1. For gastric cancer incidence, the authors should use the WHO GLOBOCAN database 2018, instead of global cancer statistics, 2012.

Thank you for indicating updated data. We corrected this point in line 3, page 7 and reference #1.

2. I cannot completely rule out the possibility that small sample size induced high concordance rate (96.2%). The authors should examine the concordance rate in more samples and multi-center.

This is an important point. Our study has several limitations because of its retrospective nature. We added this point in Discussion section, line 17, page 14. Now, we are going to planning a multi-center prospective study.

3. In Results section (page 10, the last line), Sixteen out of 18 (88.9%) patients died of…. What is the 18 patients?

Please excuse our lack of explanation. We add the following explanation in Results section, line 24, page 11: Eighteen patients died within the observational period and among them, 16 (88.9%) died of recurrent gastric cancer.”